Obesity, Stem Cells and Cancer

Madhuri Kakarala MD, PhD
Division of Hematology/Oncology
University of Michigan






Outline


- Discuss cancer stem cell model of carcinogenesis, metastasis, recurrence
- Models for study of stem cell biology; limitations/strengths/needs
- Screening system for potential interventions: dietary components eg. curcumin/piperine or drugs eg. Metformin/IL6 receptor Ab/Akt inhibitors
- Complexities of human clinical trials assessing stem cell endpoints

Epithelial and mesenchymal stem cells in carcinogenesis, metastasis and recurrence


- Cancers Originate From Tissue Stem Or Progenitor Cells
- Cancers Are "Driven" By Epithelial Cells With Stem Cell Properties supported by mesenchymal stem cells in the niche
- Stem cell properties: self renewal, differentiation, epithelial to mesenchymal transition and mesenchymal to epithelial transition
- Stem Cell Hypothesis:



Development of the Mammary Gland and Mammary Tumors




Example of dysregulated clonal expansion of stem cells




Red: ALDH1; Brown: ER
ALDH1 in breast epithelium
from BRCA1-carriers

Breast Cancer Development




Normal duct Hyperplasia In situ carcinoma Invasive carcinoma




"Cancer Stem Cell" Markers

Tumor Type	CD44	CD24	CD133	ALDH	ESA	B1	Beta-6
Breast	+	1	+/-	+		+	+
Colon	+		+	+	+		
Pancreas	+	+	+	+	+		
Prostate	+			+		+	
Brain			+				
Head/Neck	+			+		+	
Melanoma	+		+			+	

Mammosphere Assay and ALDH breast stem cell marker





ALDEFLUOR+ population and tumorigenicity



ALDEFLUOR+ population regenerates heterogeneity of the initial tumor


ALDEFLUOR+ cells have stem cell properties






Supportive role of adipocytes and adipose derived mesenchymal cells in the niche in clonal expansion, proliferation, and dissemination of cancer stem cells

EMT and MET in tumorigenesis, recurrence and metastasis




IGF1, Leptin, adiponectin and IL-6 are prosurvival cytokines for epithelial and mesenchymal stem cells




Pochampally 2009, Hursting 2010

Signaling pathways mediating the effect of the pro-inflammatory state of obesity upon cancer stem cells






Proinflammatory, proangiogenic and hematopoetic cytokines secreted by human adipose derived stem cells





The Human Stem Cell Model and Cancer Biology





DMSO control 10 µM curcumin

- A screening system for cancer treatment/risk reductive intervention efficacy
- Assay for mechanism, microRNA, profiling, protein sequencing, toxicant effects, nutrient/toxicant interactions
- In vivo biomarker of efficacy



Regulation of stem cell self renewal and clonal expansion




Figure 1. Proposed pathways involved in breast epithelial stem cell self-renewal

Curcumin's Anticarcinogenesis Mechanisms



Constitutive activation of transcription factors

- -AP -1, NFκB
- -Tumor Suppressor Genes

Modulation of Signaling


- Wnt/β catenin
- -Notch
- Hedgehog

Overexpression of

- -Oncogenes
- -Her 2
- -Growth factors eg. EGF, PDGF
- -Survival factors eg. Survivin, bcl 2, bcl-xl
- -Cyclin D1

Overexpression of


- -MMPs
- -Cox 2
- -adhesion molecules
- -chemokines
- -TNF







Piperine

- Isolate of piper nigrum and piper longum or black pepper/ hot peppers
- Inhibits
 - P-glycoprotein drug efflux
 - First pass enzymes, CYP 3A4
 - Intestinal conjugation
 - NFkB




Targeting Breast Stem Cells with the Cancer Preventive Compounds Curcumin and Piperine (1 spheres)







Effect of Curcumin and Piperine on ALDH+ cells (%)





Curcumin/Piperine's Effect on Wnt Signaling %0.48 %5.82 %13.38 ⁸ %0.89 %5.39 %0.86 %0.55 MCF7-GFP MCF7-GFP +C5 MCF7-GFP +P10 MCF7-GFP MCF7 MCF7-GFP +C10 MCF7-GFP


GFP

+C5+P10

+C10+P10








Piperine in human plasma after 50mg oral dose

Pharmacokinetics of Piperine in Two Healthy Male Volunteers



Kakarala et al. J Ag Food Chem 2010




Is dietary piperine bioavailable?

- 7 day food records, baseline and at 24 wks
 Mediterranean diet intervention
- Assess sources of piperine, peppers, black pepper, prepared foods, eggs
- Plasma samples to assay for piperine
 - at baseline and
 - at 24 wks


Piperine in human plasma!

- Mediterranean Diet
- 6 mo.s intervention
- 70 subjects, baseline only 9
- Blood drawn after 12 hr. fast
- Piperine detectable in all but3 blood samples!!
- Range 6-500 ng/mL
- Mean 100.22 ng/mL, baseline
 94.04 ng/mL, 6 mo.s
- No intervention effect



Kakarala, Cheng, Dubey, Djuric, Brenner

Metformin, TGF β and EMT Induction of tumor suppressor Let 7 and suppression of miRNA 181a



Cufi, Menendez 2010, 2011



Assessing stem cell changes as biomarkers in human clinical trials eg. PARP inhibition in women with BRCA1/2 mutations


SEQUENTIAL dose levels: 80 women with a germline BRCA1/2 Blood sample and mutation who are 20 women at **Level 1**: Veliparib Prophylactic bilateral 50 mg po BID d 1-28 planning prophylactic mastectomies preceded in the OR bilateral mastectomies and by RPFNA. Tissue 20 women at **Level 2**: Veliparib are willing to take a collected after clinical 100mg po BID d 1-28 PARP inhibitor for processing: 28+ 4 days just Blood and Dr. Kakarala to before their surgery. optional 20 women at **Level 3**: Veliparib assess stem and 150mg po qAM, 50mg qPM d 1-28 RPFNA, progenitor cell and Core changes post bx for dosina 20 women at **Level 4**: Veliparib Pre-PARP 200mg po BID d 1-28 AI DH1+ and

markers.

PI: J. Garber, DFCI, Susan G. Komen Foundation
M. Kakarala UM Site PI and Collaborator

Clinical Trial Design to Assess Cancer Stem Cell Endpoints

- Conventional imaging or molecular biomarkers such as Ki67 do not work
- Need large volumes of fresh/frozen tissue for dynamic endpoints
- Profiling potentially powerful tool
- Epigenetics key to assessing environmental/dietary exposure effects
- New tools in development for in situ imaging of individual cells for multiple markers



Funding

<u>Past</u>

- Innovative concepts in stem cell research CC -\$50,000
- Trehan Foundation -\$75,000
- NIH KL2 75% salary 9/07- 1/10
- VA 5/8 appt
- John Thomas Foundation 12/09
- Donations from Coady family

Present

- NIH K07 (9/10) 75% salary x 5 yrs. + 30K/yr research funds
- Komen Foundation Promise grant 20% salary x 5 yrs. + 75K/yr research funds (9/10)
- VA CDA 100 % salary + 65K/yr research funds 9/10 awarded but declined
- EDRN Competitive Renewal 20% salary
 x 5 yrs. + 50K/yr. research funds (9/10)
- Komen Career Catalyst Award



Acknowledgements

- Dr. Shiv Kumar Dubey, Connie Cheng, Samadhi Liyanage, Karim Tazi, Satyum Parikh, Esther Yoon, Craig Dobry, Chintaka Amarasinghe, Terrence Strawder
- Drs. Dean Brenner, Zora Djuric, Missy Tuck, Dan Normolle, and Biomedical Prevention Group
- Drs. Max Wicha, Hasan Korkaya, and Breast Stem Cell Research Group
- Drs. Kathy Cooney, John Carethers, Eric Fearon, Robb Todd, Scott Gitlin, Lisa Newman, Jennifer Griggs, Daniel Hayes, Celina Kleer
- Drs. Sharon Hoerr, Arshad Majid, Judy Garber, Kornelia Polyak, Jenny Chang, Krishna Misra, Rajendra Mehta, Kishore Chaudhry, Sunita Saxena